Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Phase III U.S. Pivotal Study Results On CSL Biotherapies Afluriaź Published In Vaccine
September 17th, 2008
Phase III pivotal study findings published in the journal Vaccine showed that two formulations of CSL Biotherapies' influenza virus vaccine Afluriaź elicited an immune response (also known as immunogenicity) in healthy adults aged 18- <65 years. The results, from a study performed at nine centers affiliated with the National Institutes of Health (NIH), met the U.S. Food and Drug Administration's (FDA) requirements for influenza vaccine immunogenicity. These data formed the basis of CSL Biotherapies' US biologics licensing application for Afluria that was approved through priority review by the FDA in September 2007. Afluria is indicated for the active immunization...
Source: Vaccine Weekly (2008-09-17)
|
